Differential activity of nucleotide analogs against tick-borne encephalitis and yellow fever viruses in human cell lines

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt

Standard

Differential activity of nucleotide analogs against tick-borne encephalitis and yellow fever viruses in human cell lines. / Binderup, Alekxander; Galli, Andrea; Fossat, Nicolas; Fernandez-Antunez, Carlota; Mikkelsen, Lotte S; Rivera-Rangel, Lizandro René; Scheel, Troels K H; Fahnøe, Ulrik; Bukh, Jens; Ramirez, Santseharay.

I: Virology, Bind 585, 2023, s. 179-185.

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt

Harvard

Binderup, A, Galli, A, Fossat, N, Fernandez-Antunez, C, Mikkelsen, LS, Rivera-Rangel, LR, Scheel, TKH, Fahnøe, U, Bukh, J & Ramirez, S 2023, 'Differential activity of nucleotide analogs against tick-borne encephalitis and yellow fever viruses in human cell lines', Virology, bind 585, s. 179-185. https://doi.org/10.1016/j.virol.2023.06.002

APA

Binderup, A., Galli, A., Fossat, N., Fernandez-Antunez, C., Mikkelsen, L. S., Rivera-Rangel, L. R., Scheel, T. K. H., Fahnøe, U., Bukh, J., & Ramirez, S. (2023). Differential activity of nucleotide analogs against tick-borne encephalitis and yellow fever viruses in human cell lines. Virology, 585, 179-185. https://doi.org/10.1016/j.virol.2023.06.002

Vancouver

Binderup A, Galli A, Fossat N, Fernandez-Antunez C, Mikkelsen LS, Rivera-Rangel LR o.a. Differential activity of nucleotide analogs against tick-borne encephalitis and yellow fever viruses in human cell lines. Virology. 2023;585:179-185. https://doi.org/10.1016/j.virol.2023.06.002

Author

Binderup, Alekxander ; Galli, Andrea ; Fossat, Nicolas ; Fernandez-Antunez, Carlota ; Mikkelsen, Lotte S ; Rivera-Rangel, Lizandro René ; Scheel, Troels K H ; Fahnøe, Ulrik ; Bukh, Jens ; Ramirez, Santseharay. / Differential activity of nucleotide analogs against tick-borne encephalitis and yellow fever viruses in human cell lines. I: Virology. 2023 ; Bind 585. s. 179-185.

Bibtex

@article{b1222c8bc2b14ee58e74567e36190c87,

title = "Differential activity of nucleotide analogs against tick-borne encephalitis and yellow fever viruses in human cell lines",

abstract = "With no approved antiviral therapies, the continuous emergence and re-emergence of tick-borne encephalitis virus (TBEV) and yellow fever virus (YFV) is a rising concern. We performed head-to-head comparisons of the antiviral activity of available nucleos(t)ide analogs (nucs) using relevant human cell lines. Eight existing nucs inhibited TBEV and/or YFV with differential activity between cell lines and viruses. Remdesivir, uprifosbuvir and sofosbuvir were the most potent drugs against TBEV and YFV in liver cells, but they had reduced activity in neural cells, whereas galidesivir retained uniform activity across cell lines and viruses. Ribavirin, valopicitabine, molnupiravir and GS-6620 exhibited only moderate antiviral activity. We found antiviral activity for drugs previously reported as inactive, demonstrating the importance of using human cell lines and comparative experimental assays when screening the activity of nucs. The relatively high antiviral activity of remdesivir, sofosbuvir and uprifosbuvir against TBEV and YFV merits further investigation in clinical studies.",

author = "Alekxander Binderup and Andrea Galli and Nicolas Fossat and Carlota Fernandez-Antunez and Mikkelsen, {Lotte S} and Rivera-Rangel, {Lizandro Ren{\'e}} and Scheel, {Troels K H} and Ulrik Fahn{\o}e and Jens Bukh and Santseharay Ramirez",

year = "2023",

doi = "10.1016/j.virol.2023.06.002",

language = "English",

volume = "585",

pages = "179--185",

journal = "Virology",

issn = "0042-6822",

publisher = "Academic Press",

}

RIS

TY - JOUR

T1 - Differential activity of nucleotide analogs against tick-borne encephalitis and yellow fever viruses in human cell lines

AU - Binderup, Alekxander

AU - Galli, Andrea

AU - Fossat, Nicolas

AU - Fernandez-Antunez, Carlota

AU - Mikkelsen, Lotte S

AU - Rivera-Rangel, Lizandro René

AU - Scheel, Troels K H

AU - Fahnøe, Ulrik

AU - Bukh, Jens

AU - Ramirez, Santseharay

PY - 2023

Y1 - 2023

N2 - With no approved antiviral therapies, the continuous emergence and re-emergence of tick-borne encephalitis virus (TBEV) and yellow fever virus (YFV) is a rising concern. We performed head-to-head comparisons of the antiviral activity of available nucleos(t)ide analogs (nucs) using relevant human cell lines. Eight existing nucs inhibited TBEV and/or YFV with differential activity between cell lines and viruses. Remdesivir, uprifosbuvir and sofosbuvir were the most potent drugs against TBEV and YFV in liver cells, but they had reduced activity in neural cells, whereas galidesivir retained uniform activity across cell lines and viruses. Ribavirin, valopicitabine, molnupiravir and GS-6620 exhibited only moderate antiviral activity. We found antiviral activity for drugs previously reported as inactive, demonstrating the importance of using human cell lines and comparative experimental assays when screening the activity of nucs. The relatively high antiviral activity of remdesivir, sofosbuvir and uprifosbuvir against TBEV and YFV merits further investigation in clinical studies.

AB - With no approved antiviral therapies, the continuous emergence and re-emergence of tick-borne encephalitis virus (TBEV) and yellow fever virus (YFV) is a rising concern. We performed head-to-head comparisons of the antiviral activity of available nucleos(t)ide analogs (nucs) using relevant human cell lines. Eight existing nucs inhibited TBEV and/or YFV with differential activity between cell lines and viruses. Remdesivir, uprifosbuvir and sofosbuvir were the most potent drugs against TBEV and YFV in liver cells, but they had reduced activity in neural cells, whereas galidesivir retained uniform activity across cell lines and viruses. Ribavirin, valopicitabine, molnupiravir and GS-6620 exhibited only moderate antiviral activity. We found antiviral activity for drugs previously reported as inactive, demonstrating the importance of using human cell lines and comparative experimental assays when screening the activity of nucs. The relatively high antiviral activity of remdesivir, sofosbuvir and uprifosbuvir against TBEV and YFV merits further investigation in clinical studies.

U2 - 10.1016/j.virol.2023.06.002

DO - 10.1016/j.virol.2023.06.002

M3 - Journal article

C2 - 37356253

VL - 585

SP - 179

EP - 185

JO - Virology

JF - Virology

SN - 0042-6822

ER -

ID: 359047463